Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity

Journal of Neuro-Oncology

Volumn 66, Issue 1-2, 2004, Pages 155-166

  Arena, Sara ^a   Barbieri, Federica ^b   Thellung, Stefano ^a   Pirani, Paolo ^b   Corsaro, Alessandro ^a   Villa, Valentina ^a   Dadati, Patrizia ^b   Dorcaratto, Alessandra ^a   Lapertosa, Gabriella ^a   Ravetti, Jean Louis ^b   Spaziante, Renato ^a   Schettini, Gennaro ^a,b   Florio, Tullio ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Meningioma; Primary cultures; Proliferation; RT PCR; Somatostatin receptors

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; KI 67 ANTIGEN; MARKER; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BCL 2; PROTEIN P53; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; THYMIDINE; TRITIUM;

ADULT; AGED; APOPTOSIS; ARTICLE; ASSAY; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MENINGIOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SIGNAL TRANSDUCTION; TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744220120     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000013498.19981.55     Document Type: Article

References (47)

1. Epelbaum J: Somatostatin in the central nervous system: Physiology and pathology modification. Prog Neurobiol 27: 63-100, 1986
2. Reichlin S: Somatostatin. N Engl J Med 309: 1495-1501, 1983
3. Florio T, Thellung S, Schettini G: Intracellular transducing mechanisms modulated by activated brain somatostatin receptors. Pharmacol Res 33: 297-305, 1996
4. Patel Y: Somatostatin and its receptor family. Frontiers Neuroendocrinol 20: 157-198, 1999
5. Koch BD, Schonbrunn A: The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membrane. Endocrinology 144: 1784-1790, 1984
6. Schettini G, Florio T, Meucci O, Landolfi E, Grimaldi M, Ventra C, Marino A: Somatostatin inhibition of adenylate cyclase activity in different brain areas. Brain Res 492: 65-71, 1989
7. Florio T, Schettini G: Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. J Mol Endo 17: 89-100, 1996
8. Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti J-L, Spaziante R, Giusti M, Schettini G: Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells, in vitro. Clin Endocrinol 59: 115-128, 2003
9. Pan MG, Florio T, Stork PJS: G protein activation of a hormone-stimulated protein-tyrosine phosphatase in human tumor cells. Science 256: 1215-1217, 1992
10. Colas B, Cambillau C, Buscail L, Zeggari M, Esteve JP, Leutre V, Thomas F, Vaysse N, Susini C: Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem 207: 1017-1024, 1992
11. Florio T, Rim C, Hershberger RE, Loda M, Stork PJS: The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol Endocrinol 8: 1289-1297, 1994
12. Florio T, Scorziello A, Fattore M, D'Alto V, Salzano S, Rossi G, Berlingieri MT, Fusco A, Schettini G: Somatostatin inhibits PC C13 thyroid clonal cell line proliferation through the modulation of phosphotyrosine phosphatase activity: Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. J Biol Chem 271: 6129-6136, 1996
13. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92(5): 1580-1584, 1995
14. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJS: Somatostatin activation of MAP kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 13: 24-37, 1999
15. Florio T, Arena S, Thellung S, Iuliano R, Corsaro A, Massa A, Pattarozzi A, Bajetto A, Trapasso F, Fusco A, Schettini G: The activation of the phosphotyrosine phosphatase η (r-PTPη) is responsible for the somatostatin inhibition of PC C13 thyroid cell proliferation. Mol Endocrinol 15: 1838-1852, 2001
16. Alderton F, Humphrey PP, Sellers LA: High-intensity p38 kinase activity is critical for p21 (cip1) induction and the antiproliferative function of G protein-coupled receptors. Mol Pharmacol 59: 1119-1128, 2001
17. Medina DL, Toro MJ, Santisteban P: Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidyl inositol 3-kinase. J Biol Chem 275: 15549-15556, 2000
18. Hildebrandt G, Scheidhauer B, Luyken C, Schicha H, Klug N, Dahmus P, Krisch B: High sensitivity of the in vivo detection of somatostatin receptors by Indium (DTPA-Octreotide) scintigraphy in meningioma patients. Acta Neurochir 126: 63-71, 1994
19. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V: Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptors subtype SST2a. Clin Cancer Res 6: 1865-1874, 2000
20. Cervera P, Videau C, Viollet C, Petrucci C, Lacombe J, Winsky-Sommerer R, Csaba Z, Helboe L, Daumas-Duport C, Reubi JC, Epelbaum J: Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol 14: 458-471, 2002
21. Lamszus K, Meyerhof W, Westphal M: Somatostatin and somatostatin receptor in the diagnosis and treatment of gliomas. J Neuro-Oncol 35: 353-364, 1997
22. Haldemann AR, Rösler H, Barth A, Waser B, Geiger L, Godoy N, Markwalder RV, Seiler RW, Sulzer M, Reubi JC: Somatostatin receptor scintigraphy in central nervous system tumors: Role of the blood-brain barrier permeability. J Nucl Med 36: 403-410, 1995
23. Luyken C, Hildebrandt G, Scheidhauer K, Krisch B, Schicha H, Klug N: 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir 127: 60-64, 1994
24. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan DM, Schettini G: Somatostatin controls Kaposi sarcoma growth through inhibition of angiogenesis. FASEB J 13: 647-655, 1999
25. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor 3 (SSTR3) mediated regulation of endothelial NOS and MAP kinase activities. Endocrinology 144: 1574-1584, 2003
26. Reubi JC, Laissue JA: Multiple actions of somatostatin in neoplastic diseases. Trends Pharmacol Sci 16: 110-115, 1995
27. Louis DN, Scheittuer BW, Budka H, V.Deimling A, Kepes JJ: Meningiomas. Pathology and Genetics of Tumors of the Nervous System, 2nd edn. In: Kleihues P, Cavenee WB (eds) pp 176-184, 2000
28. Reubi JC, Maurer R, Klijn JG, Stefanko SZ, Foekens JA, Blaauw G, Blankenstein MA, Lamberts SW: High incidence of somatostatin receptors in human meningiomas: Biochemical characterization. J Clin Endocrinol Metab 63: 433-438, 1986
29. Grzybicki DM, Moore SA. Implications of prognostic markers in brain tumors. Clin Lab Med 19: 833-847, 1999
30. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Giusti M, Giordano G, Schettini G: Somatostatin and its analogue lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells, in vitro. Eur J Endocrinol 141: 396-408, 1999
31. Florio T, Pan MG, Newman B, Hershberger RE, Civelli O, Stork PJS. Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. J Biol Chem 267: 24169-24172, 1992
32. Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M, Serio M, Pagani A, Bussolati G, Granchi S, Maggi M: Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 2: 1757-1765, 1996
33. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C, Bsucail L: Gene therapy for pancreatic carcinoma: Local and distant antitumor effects effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 10: 995-1008, 1999
34. Dutour A, Kumar U, Panetta R, Ouafik LH, Fina F, Sasi R, Patel YC: Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76: 620-627, 1998
35. Reubi JC, Schaer JC, Waser B, Mengod G: Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54: 3455-3459, 1994
36. Reubi JC, Waser B, Schaer JC, Laissue JA: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28: 836-846, 2001
37. KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 32; 970-975, 2001
38. WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neuro-Oncol 46: 205-213, 2000
39. Kostantinidou A, Korkolopoulou P, Patsouris E, Mahera H, Hranioti S, Kotsiakis X, Davaris P: Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. J Neuro-Oncol 55: 1-9, 2001
40. Aguiar PH, Agner C, Simm R, Freitas AB, Tsanaclis AM, Plese P: p53 Protein expression in meningiomas - A clinico-pathologic study of 55 patients. Neurosurg Rev 25: 252-257, 2002
41. Hakin-Smith V, Battersby RD, Maltby EL, Timperley WR, Royds JA: Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence. Neuropathol Appl Neurobiol 27: 40-49, 2001
42. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998
43. Cory S, Adams JM: The bcl-2 family: Regulators of the cellular life or death switch. Nature Cancer 2: 647-656, 2002
44. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10: 1688-1696, 1996
45. Reubi JC, Mengod G, Palacios JM, Horisberger U, Hackeng WH, Lamberts SW: Lack of evidence for autocrine feedback regulation by somatostatin in somatostatin receptor-containing meningiomas. Cell Growth Differ 1: 299-303, 1990
46. Florio T, Scorziello A, Thellung S, Salzano S, Berlingieri MT, Fusco A, Schettini G: Oncogene transformation of PC C13 clonal thyroid cell line that induces an autonomous pattern of proliferation that correlates with loss of basal and stimulated phoshotyrosine phosphatase activity. Endocrinology 138: 3756-3763, 1997
47. Limouris GS, Rassidakis A, Kondi-Paphiti A, Triantafyllou N, Manetou A, Giannakopoulos V, Toubanakis N, Psyhojios I, Stavraka A, Vlahos L: Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide. Anticancer Res 17: 1593-1597, 1997